Table 2.
Characteristics of patients aged ≥65 years who received an ECD transplant
| Characteristic | ESP Recipients (n=1520) | United States Recipients (n=446) | P Value |
|---|---|---|---|
| Donor characteristics | |||
| Age (yr), median (q1, q3) | 69 (67, 73) | 69 (67, 72) | 0.07 |
| Age ≥70 yr | 741 (49)a | 196 (44) | 0.07 |
| Male sex | 704 (46) | 192 (43) | 0.22 |
| History of diabetes | 113 (7) | 40 (9) | 0.29 |
| History of hypertension | 842 (55) | 228 (51) | 0.11 |
| Cerebrovascular accident as cause of death | 1063 (70) | 358 (80) | <0.01 |
| Recipient characteristics | |||
| Male sex | 988 (65) | 286 (64) | 0.73 |
| Race | N/A | N/A | |
| White | 315 (71) | ||
| Black | 102 (23) | ||
| Other | 49 (6) | ||
| Cause of ESRD | <0.001 | ||
| Diabetes | 141 (9) | 132 (30) | |
| Other | 1379 (91) | 307 (70) | |
| Missing | 0 | 7 | |
| Body mass index (kg/m2) | <0.001 | ||
| <30 | 1208 (89) | 293 (82) | |
| ≥30 | 150 (11) | 65 (18) | |
| Missing | 162 | 88 | |
| Time on dialysis (yr), median (q1, q3) | 3.36 (2.08, 5.16) | 2.58 (1.58, 3.87) | <0.001 |
| Panel reactive antibody | <0.001 | ||
| <5% | 1489 (98) | 315 (73) | |
| 5%–30% | 25 (2) | 86 (20) | |
| >30% | 3 (0) | 30 (7) | |
| Missing | 3 | 15 | |
| Cold ischemic time (hr) | <0.001 | ||
| 0–12 | 774 (53) | 50 (13) | |
| 12.1–24 | 652 (44) | 210 (56) | |
| >24 | 42 (3) | 118 (31) | |
| Missing | 52 | 68 | |
| Induction therapy | <0.01 | ||
| Depleting antibody | 240 (19) | 98 (24) | |
| Nondepleting antibody | 421 (32) | 151 (36) | |
| Neither | 639 (49) | 165 (40) | |
| Missing | 220 | 32 | |
| Calcineurin inhibitor | <0.001 | ||
| Tacrolimus | 344 (29) | 213 (54) | |
| Cyclosporine | 840 (70) | 142 (36) | |
| Sirolimus | 13 (1) | 41 (10) | |
| Missing | 323 | 50 | |
| Antimetabolite | <0.01 | ||
| Mycophenolate mofetil | 1107 (90) | 328 (95) | |
| Azathioprine | 119 (10) | 16 (5) | |
| Neither | 294 | 102 |
a
Values represent n (%) unless otherwise specified.